Jiang Meng-Jie, Weng Shan-Shan, Cao Ying, Li Xiao-Fen, Wang Liu-Hong, Xu Jing-Hong, Yuan Ying
From the Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou (M-JJ, S-SW, YC, X-FL, YY); Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, Chinese National Ministry of Education; Key Laboratory of Molecular Biology in Medical Sciences) Zhejiang Province (M-JJ, YC, X-FL, YY); Department of Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou (L-HW); and Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou (J-HX).
Medicine (Baltimore). 2015 Sep;94(36):e1484. doi: 10.1097/MD.0000000000001484.
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor in gastrointestinal tracts; however, the synchronous or metachronous coexistence of GIST with additional primary malignancy is not common.Here, we present an unusual case of gastric GIST with metachronous primary lung adenocarcinoma diagnosed during his adjuvant treatment with oral receptor tyrosine kinase inhibitor imatinib mesylate (400 mg daily). After 6-month use of imatinib, the patient suffered from dry cough and dyspnea. Subsequent lung biopsy demonstrated adenocarcinoma with diffuse interstitial changes.Our research emphasizes the possibility of an additional primary tumor with GIST, and reminds the clinicians to strengthen the surveillance of the additional cancer during the follow-up of GIST patients.
胃肠道间质瘤(GIST)是胃肠道最常见的间叶性肿瘤;然而,GIST与其他原发性恶性肿瘤同步或异时共存并不常见。在此,我们报告一例罕见的胃GIST病例,患者在口服受体酪氨酸激酶抑制剂甲磺酸伊马替尼(每日400毫克)辅助治疗期间被诊断出异时性原发性肺腺癌。使用伊马替尼6个月后,患者出现干咳和呼吸困难。随后的肺活检显示为伴有弥漫性间质改变的腺癌。我们的研究强调了GIST患者存在其他原发性肿瘤的可能性,并提醒临床医生在GIST患者随访期间加强对其他癌症的监测。